41 results about "Cells transplant" patented technology

Healthcare formulations, including, inventive surfactants, Active ingredient formulated as solids, liquids, or emulsions. The present disclosure provides formulations of healthcare products, such as: prescription drugs, over the counter drugs; minerals, herbal, and / or vitamin supplements; drugs administered in hospitals, clinics, physician's office, and places of palliative care; vaccines, tissue, organ, and cell transplants and / or grafts and / or infusions; and wound care formulations including topical ointments, lotions, cleaners, wipes, bandages, and dressings. The Active may be included in the formulations as a solute, a solvent, a particle, or an oil immiscible component of the formulation. The Active may be included in tablets, capsules, tinctures, liquids, or emulsions. Inventive healthcare formulations include formulations suitable for administration orally, topically, and / or by injection.

This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.

The invention relates to the technical field of nerve injury repair, in particular to a spinal cord injury repair system based on ordered collagen scaffold carried cell transplantation combined with electroacupuncture stimulation application. The invention provides a spinal cord injury repairing system, which comprises a biological material support transplanting module, a cell inoculating module and a spinal cord injury repairing module, and the electro-acupuncture stimulation module is used for applying electro-acupuncture stimulation to acupuncture points after the biological material stent inoculated with the cells is transplanted to the spinal cord injury part. According to the system, electroacupuncture stimulation and biomaterial stent transplantation cells are combined for application, the microenvironment can be remarkably improved, survival, differentiation and function integration of the transplantation cells can be promoted, meanwhile, muscle atrophy and joint degeneration are relieved, an innovative treatment system is provided for spinal cord injury, and the system has high clinical feasibility and is worthy of popularization and application. Good application prospects are realized in the field of spinal cord injury repair.

Novel methods are disclosed for treating patients with Parkinson's disease and other primary and secondary parkinsonian disorders by improving cell engraftment. Treating patients with antihyperlipidemic drugs and / or CSF-1R antagonists before, during, and / or after transplantation of DA neurons improves cell viability, engraftment, proliferation, migration, or differentiation of the administered DA neurons. Methods are disclosed for pre-treating patients to improve engraftment of administered cells. Methods are disclosed for pre-treating patients to improve engraftment of administered progenitor cells.

Healthcare formulations, including, inventive surfactants, Active ingredient formulated as solids, liquids, or emulsions. The present disclosure provides formulations of healthcare products, such as: prescription drugs, over the counter drugs; minerals, herbal, and / or vitamin supplements; drugs administered in hospitals, clinics, physician's office, and places of palliative care; vaccines, tissue, organ, and cell transplants and / or grafts and / or infusions; and wound care formulations including topical ointments, lotions, cleaners, wipes, bandages, and dressings. The Active may be included in the formulations as a solute, a solvent, a particle, or an oil immiscible component of the formulation. The Active may be included in tablets, capsules, tinctures, liquids, or emulsions. Inventive healthcare formulations include formulations suitable for administration orally, topically, and / or by injection.

The present invention addresses the problem of providing a method for obtaining mature cardiomyocytes which can be used for screening in drug development and for cell transplantation, and said problem is solved by providing a mature cardiomyocyte production method including a step for performing partial reprogramming in immature cardiomyocytes.

Nanoparticles, methods, and kits are provided for supplying nutrients and other therapeutic agents to transplanted cells. Nutrient deprivation is a significant factor which contributes to poor outcome of many cell transplants because cells receive insufficient nutrients until they are able to establish a functional microcirculation to support their metabolic and physiological needs after transplantation. Nanoparticles are provided for use in supplying nutrients and other therapeutic agents to transplanted cells to improve cell survival. Such nanoparticles can be used to supply nutrients and other factors to transplanted cells until the transplanted cells are able to develop a new microcirculation.

The application discloses a kind of fibroblast growth factor 2 and mesenchymal cell co-loaded freeze-dried collagen support and its preparation method and application, belong to the technical field of biomedical materials, by adding sulfated polysaccharide to collagen solution, it is formed freeze-dried collagen support containing sulfated polysaccharide by vacuum freeze-drying, it is combined with fibroblast growth factor 2 incubation, obtain the freeze-dried collagen support of loading fibroblast growth factor 2, again mesenchymal cell is inoculated in the freeze-dried collagen support of loading fibroblast growth factor 2, and the freeze-dried collagen support of fibroblast growth factor 2 and mesenchymal cell co-loading is prepared.The support obtained by the application can efficiently combine fibroblast growth factor 2, support the adhesion growth of mesenchymal cell simultaneously, promote mesenchymal cell to migrate to the inside of support, realize the uniform distribution of cell in support, and can promote angiogenesis, provide new and efficient carrier for cell transplantation treatment.

The invention belongs to the technical field of biological medicine, and particularly relates to composite hydrogel for promoting hiPSC-CMs in-situ maturation and a preparation method and application thereof. According to the preparation method disclosed by the invention, a compound liposome modified by quaternary ammonium chitosan and loaded with Torrin 1 is constructed, a unique three-dimensional network structure (PDN) is constructed by compounding different chitosan, and the compound liposome and the PDN are combined to obtain the composite hydrogel for embedding and delivering hiPSC-CMs. Wherein residual amine of the quaternary ammonium chitosan can slowly release drugs in an acidic microenvironment after myocardial infarction, and the cell cycle is inhibited; the PDN structure enhances the retention rate of cell transplantation; the loaded hiPSC-CMs can restore the contraction function, reduce spontaneous depolarization and action potential, reduce the risk of lethal arrhythmia and promote in-situ maturation of transplanted cells. Experiments show that the gel loaded with the hiPSC-CMs can significantly promote myocardial tissue maturation after myocardial infarction, effectively slow down ventricular remodeling and improve heart functions.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

Disclosed is a composition for supporting the survival and differentiation of neural progenitor cells (NPCs) transplanted into a site of nerve injury or disease, the composition comprising (a) a gel-forming molecule and (b) a chemokine receptor type 5 (CCR5) antagonist. Also disclosed is a method for treating nerve injury or disease in a subject, the method comprising: (a) mixing NPCs with a composition disclosed herein; and (b) administering the mixture of NPCs and the composition into the site of nerve injury or disease in the subject, thereby supporting the survival and differentiation of NPCs. Also disclosed is the use of a mixture of NPCs and a composition disclosed herein in the manufacture of a medicament for treating nerve injury or disease in a subject, the mixture being administered into the site of nerve injury or disease in the subject, thereby supporting the survival and differentiation of NPCs. Furthermore, disclosed is a kit for use in supporting the survival and differentiation of NPCs transplanted into the site of nerve injury or disease, the kit comprising: (a) a composition disclosed herein, (b) artificial cerebrospinal fluid (α-CSF), (c) CaCl2, and (d) thrombin.

The present invention relates to the technical field of immunotherapy, and discloses a method for constructing a human immune cell transplanted zebrafish model and its application. The method comprises the following steps: (1) taking zebrafish larvae 45 to 50 h after fertilization; (2) injecting human immune cells into the sinus venosus of the zebrafish larvae to obtain a human immune cell transplanted zebrafish model. This method for constructing a human immune cell transplanted zebrafish model has the advantages of low usage amount of immune cells and dosage, high detection throughput, short experimental period, no need for immunosuppression induction, convenience for observation and photographing, can greatly reduce time and economic costs, and can play a good role in the evaluation of the anti-tumor effects of human immune cells and immune checkpoint inhibitors.

The purpose of the present invention is to provide a cell inoculant and a substrate for cell transplantation, which can be subcultured without causing cell transformation and can be efficiently implanted into cells. Provided are an inoculant and a transplantation base material for promoting the implantation of cultured corneal endothelial cells or corneal endothelial alternative cells, each of which contains a phenolphthalein derivative. The inoculant and the substrate for transplantation can promote adhesion of cells during passage operation and implantation of cells during transplantation.

The present invention belongs to the field of biomedicine, and discloses a pharmaceutical composition, its application in the preparation of a drug for treating lymphopenia, and an anti-tumor drug. The pharmaceutical composition provided by the present invention comprises thymosin α1 and recombinant human interleukin-2. Through the synergistic cooperation of thymosin α1 and recombinant human interleukin-2, it can act well on the immune system of tumor patients damaged by treatment means such as cancer cell attack, chemotherapy, cell transplantation or targeted therapy, regulate the expression balance of immune factors related to the immune system reconstruction, improve the activity of normal lymphocytes, achieve immune system reconstruction to a certain extent, promote the proliferation of lymphocytes, especially T cell subsets, relieve or treat lymphopenia caused by chemotherapy in tumor patients, and the pharmaceutical composition can also synergistically enhance the therapeutic effect of existing chemotherapy drugs, promote the clearance of cancer cells, and achieve a better anti-tumor therapeutic effect.

The present invention relates to methods for non-invasive detection of transplantation complications (e.g., rejection, infection, vascular failure, inflammation) or the risk thereof after tissue / organ / cell transplantation. The present methods allow for early, effective, and continuous monitoring of transplant health in a pigment-agnostic manner.

A composition, kit, use and method thereof. The primer, the probe and the corresponding detection reagent system are designed on a BK virus specific sequence, compared with an existing ELISA detection method, the detection sensitivity and the window period are greatly improved, meanwhile, the primer and probe design effectively avoids the conditions of missing detection and false positive detection, and extremely high detection sensitivity and specificity are achieved. Meanwhile, the operation is simple, the detection is quick, the detection timeliness is good, and a good quick detection scheme is particularly provided for clinical conditions such as sudden hyperpyrexia of transplanted (organ transplantation or cell transplantation) patients.

The invention discloses autologous fat transplantation equipment for increasing the survival rate of fat cells, and relates to the technical field of fat cell transplantation. Comprising an adipocyte transplantation processing mechanism, the adipocyte transplantation processing mechanism comprises a cell transplantation box, and a control panel is installed on the surface of the cell transplantation box; the device can conveniently extract transplanted and extracted fat cells, is beneficial to efficiently treating the transplanted fat cells, improves the fat cell transplantation and extraction effect, reduces the probability of errors caused by manual extraction of the fat cells by medical staff, can ensure that the fat cells are transplanted and extracted in a closed and sterile environment, and improves the survival rate of the fat cells. The fat cell transplantation and extraction device is simple in structure and convenient to use, the survival rate of fat cell transplantation and extraction is increased, medical articles for fat cell extraction can be stored, medical staff can conveniently operate in the fat cell transplantation and extraction work, the fat cell transplantation efficiency of the medical staff is improved, and convenience is provided for the staff.

To provide adult neural stem cells and various adult pluripotent cells for the treatment of neurodegenerative diseases, new methods and compositions for treatment of neurodegenerative diseases.SOLUTION: Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendants e.g. bone marrow-derived neural regenerating cells in the treatment of various neurodegenerative disorders. In certain embodiments, bone marrow-derived neural regenerating cells transplanted to sites of neural degeneration stimulate growth and / or survival of host neurons.SELECTED DRAWING: None

The present invention discloses a cell storage and transplantation device for small animals under the renal capsule, and relates to the field of experimental instruments for islet transplantation. The cell storage and transplantation device for small animals under the renal capsule includes two major parts: a storage tube and a storage box. The storage tube includes an outer tube and an inner tube. The inner side of the storage box ice box is provided with six placement slots. The device provided by the present invention can directly store cell suspensions. The storage tube can be directly placed in a low-speed centrifuge for centrifugation. The cells will settle to the lower section of the inner tube of the storage tube. The storage tube with centrifuged cells can be directly placed in a matching storage box for storage and transportation. The cells do not need to be transferred before cell transplantation, and the cell viability is greatly improved. The inner tube of the storage tube is compatible with the size of a 10μL pipette, and the transplantation can be directly performed with a 10μL pipette. When injecting, the round closed end of the gel at the end of the lower section of the inner tube of the storage tube is peeled off, and the cell transplantation can be performed directly.

Provided herein are methods and systems of transplant cells and growing an ectopic tissue in a lymph node of a subject. In certain embodiments, the methods and systems provided herein enable minimally invasive cell transplantation to treat patients in need thereof. In certain embodiments, the methods and systems provided herein include the use of ultrasound endoscopy.

The present disclosure relates to a catechol group- or pyrogallol group-functionalized biocompatible polymer hydrogel patch having excellent biocompatibility and tissue adhesion, and uses for drug delivery, cell transplantation and tissue regeneration using the same. The biocompatible polymer hydrogel patch functionalized with the catechol group or pyrogallol group of the present disclosure has remarkably excellent mechanical properties and tissue adhesion compared with a solution-based bulk hydrogel. Therefore, it can load cells and a drug in vivo for a long time and also safely and efficiently deliver the cells and the drug to a target site.

The present disclosure relates to a porous scaffold having excellent tissue engineering characteristics and a method for preparing the same. The scaffold according to the present disclosure not only can be prepared by a simple process, but also can exhibit a remarkably excellent cell engraftment rate as well as high tensile strength and biocompatibility so that it can be usefully used as a support composition for human body transplantation of various uses, including artificial ligaments and supports for reinforcing the abdominal wall.

The invention provides a scaffold-free 3D hepatocyte micro-tissue as well as a preparation method and application of the scaffold-free 3D hepatocyte micro-tissue. According to the method, through a one-step transplantation strategy, hepatocytes and interstitial cells are mixed and then subjected to 3D co-culture, and the scaffold-free 3D hepatocyte micro-tissue with a tissue structure similar to that of a natural liver is prepared. According to the method, the step of repeated injection in the traditional technology is simplified, the clinical operability is improved, and the prepared 3D hepatocyte micro-tissue can be widely applied to drug screening, toxicity testing, establishment of a liver disease model, liver tissue engineering and cell transplantation and treatment of liver diseases.

An application of using n-butylidenephthalide (BP) in dopamine precursor cell transplantation treatment, including using n-butylidenephthalide (BP) to improve the treatment efficacy of dopamine precursor cell transplantation treatment and using n-butylidenephthalide (BP) and dopamine precursor cells treated by n-butylidenephthalide (BP) in dopamine precursor cell transplantation treatment. The foregoing application is particularly related to using n-butylidenephthalide (BP) to improve the efficacy of dopamine precursor cell transplantation treatment in treating Parkinson's disease.

Novel nucleic acid compositions, vector systems, modified cells, isolated peptides, isolated nucleic acid sequences and pharmaceutical compositions that encode or express T cell receptor components directed against haematopoietic-restricted minor histocompatibility antigens (MiHAs) are provided herein. These novel components may be used in the treatment of a subject having a haematological malignancy, particularly after the subject has undergone allogeneic stem cell transplantation (alloSCT). Associated methods for treating such subjects are also provided herein.

To provide the first description of hESC-derived cells transplanted into human patients, wherein results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD).SOLUTION: Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at a transplant site in both patients, with subsequent evidence that cells had attached and integrated into a native RPE layer. No signs of inflammation or hyperproliferation were observed. HESC-derived RPE cells showed no signs of rejection or tumorigenicity at a time of this report. Visual measurements suggest improvement in both patients.SELECTED DRAWING: Figure 1A-B

Disclosed is a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into a neurological injury or disease site, the composition comprising: (a) a gel forming molecule; and (b) a chemokine receptor type 5 (CCR5) antagonist. Also disclosed is a method of treating a neurological injury or disease of a subject, comprising (a) mixing NPCs with the composition as disclosed herein; and (b) administering a mixture of the NPCs and the composition into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Also disclosed is use of a mixture of NPCs and the composition as disclosed herein in the manufacture of a medicament for treating a neurological injury or disease of a subject, wherein the mixture is to be administered into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Further disclosed is a kit for use in supporting survival and differentiation of NPCs grafted into a neurological injury or disease site, the kit comprising: (a) the composition as disclosed herein; (b) artificial cerebral spinal fluid (a-CSF); (c) CaCl2; and (d) thrombin.

Disclosed is a composition for supporting survival and differentiation of neural precursor cells (NPCs) grafted into a neurological injury or disease site, the composition comprising: (a) a gel forming molecule; and (b) a chemokine receptor type 5 (CCR5) antagonist. Also disclosed is a method of treating a neurological injury or disease of a subject, comprising (a) mixing NPCs with the composition as disclosed herein; and (b) administering a mixture of the NPCs and the composition into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Also disclosed is use of a mixture of NPCs and the composition as disclosed herein in the manufacture of a medicament for treating a neurological injury or disease of a subject, wherein the mixture is to be administered into a neurological injury or disease site of the subject, to thereby support survival and differentiation of the NPCs. Further disclosed is a kit for use in supporting survival and differentiation of NPCs grafted into a neurological injury or disease site, the kit comprising: (a) the composition as disclosed herein; (b) artificial cerebral spinal fluid (a-CSF); (c) CaCl2; and (d) thrombin.

A two-dimensional lattice or mesh scaffold for therapeutic cell implants is disclosed as well as methods for manufacture and use. The lattice is constructed of crisscrossing capillaries of hydrophobic parylene, such as parylene AF4, that may be coated with a hydrophilic polymer, such as parylene C, for cell adhesion. At each intersection of the crisscross, the intersecting capillaries are internally connected so as to allow oxygen to flow freely within. The walls of the capillaries are thin enough to be permeable to oxygen, on the scale of a micron thick, so that oxygen can flow through the lattice and permeate through the capillary walls. For some implants, cells are sandwiched between two or more lattices, the cells being slightly held apart from aggregation with each other by the lattice holes. The implants may then be surgically implanted within a subject.

The present invention relates to a method for isolating dopaminergic neurons and to a pharmaceutical composition for the treatment of Parkinson's disease containing dopaminergic neurons isolated by said method. The method for isolating dopaminergic neurons comprises a step for isolating dopaminergic neurons that are positive for trophoblastic glycoprotein (TPBG), such that the dopaminergic neurons isolated by this method exhibit greater cellular efficacy upon transplantation and greater transplant safety, thus enabling their effective use in cell transplantation for the treatment of Parkinson's disease.